{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:09:56Z","timestamp":1761894596283,"version":"3.37.3"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1124\/jpet.107.128280","type":"journal-article","created":{"date-parts":[[2007,10,6]],"date-time":"2007-10-06T00:25:56Z","timestamp":1191630356000},"page":"299-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Demonstration of Proof of Mechanism and Pharmacokinetics and Pharmacodynamic Relationship with 4\u2032-Cyano-biphenyl-4-sulfonic Acid (6-Amino-pyridin-2-yl)-amide (PF-915275), an Inhibitor of 11\u03b2-Hydroxysteroid Dehydrogenase Type 1, in Cynomolgus Monkeys"],"prefix":"10.1016","volume":"324","author":[{"given":"B. Ganesh","family":"Bhat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natilie","family":"Hosea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fanjul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Thalacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Rejto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.107.128280_bib1","doi-asserted-by":"crossref","unstructured":"Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, et al. (2003) Selective inhibition of 11\u03b2-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144: 4755-4762.","DOI":"10.1210\/en.2003-0344"},{"key":"10.1124\/jpet.107.128280_bib2","doi-asserted-by":"crossref","unstructured":"Barf T, Vallg\u00e5rda J, Emond R, H\u00e4ggstr\u00f6m C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, et al. (2002) Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11\u03b2-hydroxysteroid dehydrogenase type 1. J Org Chem 45: 3813-3815.","DOI":"10.1021\/jm025530f"},{"key":"10.1124\/jpet.107.128280_bib3","doi-asserted-by":"crossref","unstructured":"Basu R, Singh R, Basu A, Chittilapilly E, Johnson C, Toffolo G, Cobelli C, and Rizza R (2004) Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase (11beta-hsd) type 1 pathway. Diabetes 53: 2051-2059.","DOI":"10.2337\/diabetes.53.8.2051"},{"key":"10.1124\/jpet.107.128280_bib4","doi-asserted-by":"crossref","unstructured":"Beauregard C, Dickstein G, and Lacroix A (2002) Classic and recent etiologies of Cushing\u2019s syndrome: diagnosis and therapy. Treat Endocrinol 1: 79-94.","DOI":"10.2165\/00024677-200201020-00002"},{"key":"10.1124\/jpet.107.128280_bib5","doi-asserted-by":"crossref","unstructured":"Bujalska I, Shimojo M, Howie A, and Stewart PM (1997) Human 11 beta-hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 62: 77-82.","DOI":"10.1016\/S0039-128X(96)00163-8"},{"key":"10.1124\/jpet.107.128280_bib6","doi-asserted-by":"crossref","unstructured":"Castro A, Zhu JX, Alton GR, Rejto P, and Ermolieff J (2007) Assay optimization and kinetic profile of the human and the rabbit isoforms of 11beta-HSD1. Biochem Biophys Res Commun 357: 561-566.","DOI":"10.1016\/j.bbrc.2007.04.005"},{"key":"10.1124\/jpet.107.128280_bib7","doi-asserted-by":"crossref","unstructured":"Cooper M, Rabbitt E, Goddard P, Bartlett W, Hewison M, and Stewart P (2002) Osteoblastic 11b-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17: 979-986.","DOI":"10.1359\/jbmr.2002.17.6.979"},{"key":"10.1124\/jpet.107.128280_bib8","doi-asserted-by":"crossref","unstructured":"Davani B, Khan A, Hult M, Martensson E, Okret S, Efendic S, Jornvall H, and Oppermann U (2000) Type 1 11beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J Biol Chem 275: 34841-34844.","DOI":"10.1074\/jbc.C000600200"},{"key":"10.1124\/jpet.107.128280_bib9","doi-asserted-by":"crossref","unstructured":"e Silva JA (2005) Overview of the field. Metabolism 54 (5 Suppl 1): 5-9.","DOI":"10.1016\/j.metabol.2005.01.005"},{"key":"10.1124\/jpet.107.128280_bib10","doi-asserted-by":"crossref","unstructured":"Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, et al. (2005) 11\u03b2-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202: 517-527.","DOI":"10.1084\/jem.20050119"},{"key":"10.1124\/jpet.107.128280_bib11","doi-asserted-by":"crossref","unstructured":"Kershaw E, Morton N, Dhillon H, Ramage L, Seckl J, and Flier J (2005) Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54: 1023-1031.","DOI":"10.2337\/diabetes.54.4.1023"},{"key":"10.1124\/jpet.107.128280_bib12","doi-asserted-by":"crossref","unstructured":"Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, et al. (1997) 11beta-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity and stress. Proc Natl Acad Sci U S A 94: 14924-14929.","DOI":"10.1073\/pnas.94.26.14924"},{"key":"10.1124\/jpet.107.128280_bib13","doi-asserted-by":"crossref","unstructured":"Lesko LJ, Rowland M, Peck CC, and Blaschke TF. (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol 40: 803-814.","DOI":"10.1177\/00912700022009530"},{"key":"10.1124\/jpet.107.128280_bib14","doi-asserted-by":"crossref","unstructured":"Liu Y, Nakagawa Y, Wang Y, Sakurai R, Tripathi P, Lutfy K, and Friedman T (2005) Increased glucocorticoid receptor and 11\u03b2-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db\/db mice. Diabetes 54: 32-40.","DOI":"10.2337\/diabetes.54.1.32"},{"key":"10.1124\/jpet.107.128280_bib15","doi-asserted-by":"crossref","unstructured":"Masuzaki H, Paterson J, Shinyama H, Morton N, Mullins J, Seckl J, and Flier JA (2001) Transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170.","DOI":"10.1126\/science.1066285"},{"key":"10.1124\/jpet.107.128280_bib16","doi-asserted-by":"crossref","unstructured":"Paterson JM, Seckl JR, and Mullins JJ (2005) Genetic manipulation of 11\u03b2-hydroxysteroid dehydrogenases in mice. Am J Physiol Regul Integr Comp Physiol 289: R642-R652.","DOI":"10.1152\/ajpregu.00017.2005"},{"key":"10.1124\/jpet.107.128280_bib17","doi-asserted-by":"crossref","unstructured":"Robert CA, Rooyackers O, and Walker BR (2003) Effects of the 11\u03b2-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88: 285-291.","DOI":"10.1210\/jc.2002-021194"},{"key":"10.1124\/jpet.107.128280_bib18","doi-asserted-by":"crossref","unstructured":"Tomlinson JW, Sherlock M, Hughes B, Hughes SV, Kilvington F, Bartlett W, Courtney R, Rejto P, Carley W, and Stewart PM (2007) Inhibition of 11beta-HSD1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 92: 857-864.","DOI":"10.1210\/jc.2006-2325"},{"key":"10.1124\/jpet.107.128280_bib19","doi-asserted-by":"crossref","unstructured":"Tomlinson JW and Stewart PA (2005) Mechanisms of disease: selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab 1: 92-99.","DOI":"10.1038\/ncpendmet0023"},{"key":"10.1124\/jpet.107.128280_bib20","doi-asserted-by":"crossref","unstructured":"Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, and Stewart PM (2004) 11beta-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25: 831-866.","DOI":"10.1210\/er.2003-0031"},{"key":"10.1124\/jpet.107.128280_bib21","doi-asserted-by":"crossref","unstructured":"Valsamakis G, Anwar A, Tomlinson JW, Shackleton CHL, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, et al. (2004) 11\u03b2-Hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 89: 4755-4761.","DOI":"10.1210\/jc.2003-032240"},{"key":"10.1124\/jpet.107.128280_bib22","doi-asserted-by":"crossref","unstructured":"Walker B, Connacher A, Lindsay R, Webb D, and Edwards C (1995) Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80: 3155-3159.","DOI":"10.1210\/jcem.80.11.7593419"},{"key":"10.1124\/jpet.107.128280_bib23","doi-asserted-by":"crossref","unstructured":"Walker BR (2001) Steroid metabolism in metabolic syndrome X. Best Pract Res Clin Endocrinol Metab 15: 111-122.","DOI":"10.1053\/beem.2000.0123"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524342351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524342351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.107.128280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:29:43Z","timestamp":1740004183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524342351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0022356524342351"],"URL":"https:\/\/doi.org\/10.1124\/jpet.107.128280","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demonstration of Proof of Mechanism and Pharmacokinetics and Pharmacodynamic Relationship with 4\u2032-Cyano-biphenyl-4-sulfonic Acid (6-Amino-pyridin-2-yl)-amide (PF-915275), an Inhibitor of 11\u03b2-Hydroxysteroid Dehydrogenase Type 1, in Cynomolgus Monkeys","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.107.128280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2008 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}